Skip to main content
Log in

Investigational Antiarrhythmic Agents

  • Published:
Cardiac Electrophysiology Review

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788.

    Google Scholar 

  2. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990;82:1106-1116.

    Google Scholar 

  3. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992;20:527-532.

    Google Scholar 

  4. Lee KS. Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inwardNa1 current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992; 262:99-108.

    Google Scholar 

  5. Yang T, Snyders DJ, Roden DM. Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation 1995;91:1799-1806.

    Google Scholar 

  6. Yue L, Feng J, Li GR, Nattel S. Characterization of an ultrarapid delayed rectifier potassium channel involved in canine atrial repolarization. J Physiol (Lond) 1996;496:647-662.

    Google Scholar 

  7. Li GR, Feng J, Wang Z, Fermini B, Nattel S. Adrenergic modulation of ultrarapid delayed rectifier K+ current in human atrial myocytes. Circ Res 1996;78:903-915.

    Google Scholar 

  8. Jurkiewicz NK, Sanguinetti MC. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ Res 1993;72:75-83.

    Google Scholar 

  9. Sager PT. The frequency-dependent effects of dofetilide in humans. Circulation 1995;92:1I-744. (Abstract).

    Google Scholar 

  10. Bargheer K, Bode F, Klein HU, Trappe HJ, Franz MR, Lichtlen PR. Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent. Eur Heart J 1994;15:1409-1414.

    Google Scholar 

  11. Yuan S, Wohlfart B, Rasmussen HS, Olsson S, Blomstrom-Lundqvist C. Effect of dofetilide on cardiac repolarization in patients with ventricular tachycardia. A study using simultaneous monophasic action potential recordings from two sites in the right ventricle. Eur Heart J 1994;15:514-522.

    Google Scholar 

  12. Sedgwick ML, Rasmussen HS, Cobbe SM. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris. Am J Cardiol 1992;70:1432-1437.

    Google Scholar 

  13. Nademanee K, Bailey W, O'Neill G, Satler C, Freidrich T. Electrophysiologic and hemodynamic effects of dofetilide in patients with left ventricular function: a randomized, double-blind, placebo-controlled study. PACE 1998;In press: (Abstract)

  14. DeCara J, Pollak A, Dubrey S, Briggs L, Falk R. Positive atrial inotropic effects of dofetilide following cardioversion of atrial fibrillation. J Am Coll Cardiol 1998;432A-433A.

  15. Singh S, Berk M, Yellen L, et al. Efficacy and safety of oral dofetilide in maintaining normal sinus in patients with atrial fibrillation/flutter: A multicenter study. Circulation 1998;96(8):I383:2145-2145.(Abstract).

    Google Scholar 

  16. Singh S, Berk M, Zoble R, Abrahamson D, Satler C, Freidrich T. Oral dofetilide for conversion of patients with chronic atrial fibrillation or atrial flutter to normal sinus rhythm: A multicenter study. J Am Coll Cardiol 1998;31: 369A-370A.(Abstract).

    Google Scholar 

  17. Singh S, Berk M, Yellen L, Abrahamson D. Restoration and maintenance of sinus rhythm reduces frequency and severity of symptoms associated with atrial fibrillation and flutter. PACE 1998;In press: (Abstract)

  18. Bashir Y, Thomsen PE, Kingma JH, Moller M, Wong C, Cobbe SM, Jordaens L, Campbell RW, Rasmussen HS, Camm AI. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group. Am J Cardiol 1995;76:1040-1044.

    Google Scholar 

  19. Ferguson J. Clinical trials. Clin Cardiol 1998;21:51-54.

    Google Scholar 

  20. Waldo AL, Camm AJ, de RH, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with Oral d-Sotalol. Lancet 1996;348:7-12.

    Google Scholar 

  21. Fermini B, Jurkiewicz NK, Jow B, Guinosso PJJ, Baskin EP, Lynch JJJ, Salata JJ. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 1995;26:259-271.

    Google Scholar 

  22. Salata J, Brooks R. Pharmacology of azimilide dihydrochloride (NE-10064), a class III antiarrhythmic agent. Cardiovasc Drug Rev 1997;15(2):137-156.

    Google Scholar 

  23. Nair LA, Grant AO. Emerging class III antiarrhythmic agents: Mechanism of action and proarrhythmic potential. Cardiovasc Drugs Ther 1997;11:149-167.

    Google Scholar 

  24. Liu L, Nattel S. Relative effects of an IKr selective blocker (Dofetilide) and a drug with significant IKs blocking action (Azimilide) in experimental atrial fibrillation. Can J Cardiol 1996;12(Suppl E). (Abstract).

  25. Drexler AP, Micklas JM, Brooks RR. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction. J Cardiovasc Pharmacol 1996;28:848-855.

    Google Scholar 

  26. Friedrichs GS, Abreu JN, Driscoll EMJ, Borlak J, Lucchesi BR. Antifibrillatory efficacy of long-term tedisamil administration in a postinfarcted canine model of ischemic ventricular fibrillation. J Cardiovasc Pharmacol 1998;31:56-66.

    Google Scholar 

  27. Chi L, Park JL, Friedrichs GS, Banglawala YA, Perez MA, Tanhehco EJ, Lucchesi BR. Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart. Br J Pharmacol 1996;117:1261-1269.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sager, P.T. Investigational Antiarrhythmic Agents. Card Electrophysiol Rev 2, 232–235 (1998). https://doi.org/10.1023/A:1009956806133

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1009956806133

Keywords

Navigation